1 Berinstein N L, Grillo-Lopez A J, White C A, et al. Association of serum Rituximab(IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin''s lymphoma. Ann Oncol, 1998, 9: 995-1001？？
[3]
2 Van Meerten T, Claessen M J, Hagenbeek A. The CD20/a CD20''suicide''system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther, 2006, 13: 789-797？？
[4]
3 Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol, 2002, 29(suppl 2): 2-9
[5]
4 Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol, 2008, 143: 607-621？？
[6]
5 Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 2007, 26: 3629-3636？？
[7]
6 Polido-Pereira J, Ferreira D, Rodrigues A M. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci, 2009, 1173: 712-720？？
[8]
7 Korhonen R, Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol, 2010, 106: 13-21
[9]
8 Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol, 2010, 29: 707-716？？
[10]
9 Lui N L, Thumboo J, Fong K Y. A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy. Int J Rheum Dis, 2009, 12: 366-369？？
[11]
10 Troiano M, Lotti T. Rituximab in dermatological diseases. G Ital Dermatol Venereol, 2009, 144: 495-499
12 Harrison J S, Gill A, Hoare M. Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces. Biotechnol Bioeng, 1998, 59: 517-519？？
[14]
13 Zhen Y S, Ming X Y, Yu B, et al. A new macromolecular antitumor antibiotic, C-1027. Ⅲ. Antitumor activity. J Antibiot(Tokyo), 1989, 42: 1294-1298
[15]
14 Shao R G. Pharmacology and therapeutic applications of enediyne antitumor antibiotics. Curr Mol Pharmacol, 2008, 1: 50-60？？
[16]
15 Shao R G, Zhen Y S. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem, 2008, 8: 123-131？？
[17]
16 Zhen Y Z, Lin Y J, Li Y, et al. Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice. Acta Pharmacol Sin, 2009, 30: 1025-1032？？
20 Gao R J, Liang Y X, Li D D. Effect of lidamycin on telomerase activity in human hepatoma BEL-7402 cells. Biomed Environ Sci, 2007, 20: 189-197
[21]
21 Huang Y H, Shang B Y, Zhen Y S. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol, 2005, 11: 3980-3984
[22]
22 Miao Q F, Liu X Y, Shang B Y, et al. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity. Anticancer Drugs, 2007, 18: 127-137？？
[23]
23 Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol, 2006, 34: 753-759？？
[24]
24 Berdeja J G, Hess A, Lucas D M, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res, 2007, 13: 2392-2399？？
[25]
25 Van de Loosdrecht A A, Huijgens P C, Ossenkoppele G J. Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin''s lymphoma. Curr Opin Hematol, 2004, 11: 419-425？？
[26]
26 Xu Y J, Li D D, Zhen Y S. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemoth Pharm, 1990, 27: 41-46
[27]
27 Sugimoto Y, Otani T, Oie S, et al. Mechanism of action of a new macromolecular antitumor antibiotic, C-1027. J Antibiot(Tokyo), 1990, 43: 417-421
[28]
28 Kennedy A D, Beum P V, Solga M D, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol, 2004, 172: 3280-3288
[29]
29 Dillman R O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev, 1999, 18: 465-471？？
[30]
30 Beerman T A, Gawron L S, Shin S, et al. C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells. Cancer Res, 2009, 69: 593-598？？
